NanoViricides (NNVC) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
NanoViricides, Inc. has revised its License Agreement with TheraCour Pharma, Inc., deferring cash milestone payments until the company achieves a “Revenue Event,” while also capping the payout at 50% of recognized profits. Furthermore, the company has extended its Line of Credit maturity date with Dr. Anil R. Diwan to December 31, 2025, with no funds drawn to date. In a separate move to ease financial pressure, NanoViricides has also agreed with TheraCour to suspend the advance payment requirement, applying any available funds to cover outstanding invoices as it seeks to raise additional capital.
For further insights into NNVC stock, check out TipRanks’ Stock Analysis page.